Performance Status Is a Predictive Factor of Improvement after Colonic Stenting in Patients with Malignant Stenosis due to Extraparenteral Malignant Tumors

Table 3

Univariate analysis of factors for clinical improvement.

	Improvement ()	Nonimprovement ()	value
Age (≧70, <70)	8, 6	4, 3	0.99
Sex (M, F)	7, 7	3, 4	0.75
Albumin (≧2.5, <2.5)	11, 3	5, 2	0.46
Location (right, left)	1, 13	0, 7	0.26
Stent (Wall/Niti-S)	4, 10	3, 4	0.53
Length of stenosis (>4 cm, ≦4 cm)	9, 5	3, 4	0.42
Stent diameter (≧22 mm, <22 mm)	8, 6	4, 3	0.43
Chemotherapy (+, -)	3, 11	3, 4	0.42
Ascites (+, -)	3, 11	4, 3	0.35
Pre-PS (≦2, >2)	12, 2	3, 4	0.04
Adverse events (+, -)	0, 12	2, 5	0.03

PS: performance status; M: male; F: female; Wall: WallFlex colonic stent (Boston Scientific Co., Ltd., MA, USA); Niti-S: Niti-S colonic stent (Taewoong Co., Ltd., Busan, Korea).